GeneQuine (Teilexit) Exit
GeneQuine Biotherapeutics is a biotech company focused on the development of gene therapy-based drugs for treatment of musculoskeletal disorders. In the lead program GeneQuine develops drug candidates with potentially disease-modifying activity for treatment of osteoarthritis.
In 2017, one of GeneQuine's lead candidates was acquired by the US pharma company Flexion Therapeutics Inc.
Dr. Stanislav Plutizki
Dr. Kilian Guse
HTGF Financing Series A GeneQuine
GeneQuine Biotherapeutics Closes Seed Financing with High-Tech Gründerfonds and Innovationsstarter Fonds Hamburg